Αν είμαι σίγουρος για κάτι, είναι πως οι Γιατροί έχουν πρόσβαση σε χιλιάδες περιστατικά, και δεν περιμένουν εμένα με τα λίγα περιστατικά που έχω στον κύκλο των γνωστών μου. Και χαρακτηρίζεις εμένα μεταλλαγμένο, εσύ που μεταμφιέζεσαι σε γυναίκα; Για φαντάσου θράσος!!!!!!!!!!!!!
Σου χω καλα νεα μεταλλαγμενε εσενα και του μοσχαριου των 200 κιλων Νικ.
Α.
PERSPECTIVE
INFECTIOUS DISEASES
Informed consent disclosure to vaccine trial subjects of risk of
COVID-19 vaccines worsening clinical disease
Results of the study: COVID-19 vaccines designed to elicit neutralis-
ing antibodies may sensitise vaccine recipients to more severe dis-
ease than if they were not vaccinated. Vaccines for SARS, MERS and
RSV have never been approved, and the data generated in the devel-
opment and testing of these vaccines suggest a serious mechanistic
concern: that vaccines designed empirically using the traditional ap-
proach (consisting of the unmodified or minimally modified corona-
virus viral spike to elicit neutralising antibodies), be they composed
of protein, viral vector, DNA or RNA and irrespective of delivery
method, may worsen COVID-19 disease via antibody-dependent
enhancement (ADE). This risk is sufficiently obscured in clinical trial
protocols and consent forms for ongoing COVID-19 vaccine trials
that adequate patient comprehension of this risk is unlikely to occur,
obviating truly informed consent by subjects in these trials.
Β.
CCP Virus Variant Affects Vaccinated People More Than Unvaccinated People: Study
BY
JACK PHILLIPS
April 11, 2021 Updated: April 13, 2021
A study from
Tel Aviv University found that a
South African variant of the
CCP (Chinese Communist Party) virus affects people vaccinated with the Pfizer shot more than unvaccinated people.
The study, which has not yet been peer-reviewed, indicated that the B.1.351 variant of the virus was found eight times more in individuals who were vaccinated—or 5.4 percent against 0.7 percent—against those who were not vaccinated. Clalit Health Services, a top Israeli health care provider, also helped in the study.
Οποιος θελει να παει να διαβασει ολοκληρα τα αρθρα.
Εν συντομια οι εμβολιασμενοι οταν ελθουν σε επαφη εκ νεου με τον φυσικο ιο εχουν πολλαπλασιο κινδυνο να αρρωστησουν βαρεια και να πεθανουν απο τους ανεμβολιαστους.
Σε επαφη δε με τις μεταλλαξεις του ιου ειναι 6-8 φορες πιο ευαλωτοι να εκδηλωσουν την ασθενεια.
REFERENCES
1. Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus
AD. Vaccine-induced enhancement of viral infections. Vaccine.
2009;27:505-512.
2. Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of infection
and disease pathogenesis to guide RSV vaccine development. Front
Immunol. 2019;10:1675.
3. Chen WH, Hotez PJ, Bottazzi ME. Potential for developing a SARS-
CoV receptor-binding domain (RBD) recombinant protein as a het-
erologous human vaccine against coronavirus infectious disease
(COVID)-19. Human Vacc Immunother. 2020;16:1239-1242.
4. Jiang S, He Y, Liu S. SARS vaccine development. Emerg Infect Dis.
2005;11:1016-1020.
5. Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with
SARS coronavirus vaccines leads to pulmonary immunopathology
on challenge with the SARS virus. PLoS One. 2012;7:e35421.
6. Wang Q, Zhang L, Kuwahara K, et al. Immunodominant SARS coro-
navirus epitopes in humans elicited both enhancing and neutral-
izing effects on infection in non-human primates. ACS Infect Dis.
2016;2:361-376.
7. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its
receptor damages islets and causes acute diabetes. Acta Diabetol.
2010;47:193-199.
8. Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung
injury by skewing macrophage responses during acute SARS-CoV
infection. JCI insight. 2019;4:e123158.
9. Liu ZL, Liu Y, Wan LG, et al. Antibody profiles in mild and severe
cases of COVID-19. Clin Chem. 2020;66:1102–1104.
10. Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and
immunodominant sites on the SARS-CoV-2 spike receptor-bind-
ing domain by structure-guided high-resolution serology. Cell.
2020;S0092-8674:31234-4
11. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody
responses to SARS-CoV-2 infection in convalescent individuals.
bioRxiv. 2020.
12. Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent advances in
the vaccine development against middle east respiratory syn-
drome-coronavirus. Front Microbiol. 2019;10:1781.
13. Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273
Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med.
2020;383:1544–1555.
14. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study of
COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:
589–593.
15. Becerra-Flores M, Cardozo T. SARS-CoV-2 viral spike G614 mutation
exhibits higher case fatality rate. Int J Clin Pract. 2020;74:e13525.
16. Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in
SARS-CoV-2 spike: evidence that D614G increases infectivity of
the COVID-19 virus. Cell. 2020;182:812-827.e819.
17. Mansbach RA, Chakraborty S, Nguyen K, Montefiori D, Korber
B, Gnanakaran S. The SARS-CoV-2 spike variant D614G favors an
open conformational state. bioRxiv. 2020.
18. Zhang L, Jackson C, Mou H, et al. The D614G mutation in the SARS-
CoV-2 spike protein reduces S1 shedding and increases infectivity.
bioRxiv. 2020.
19. Wendler D. What should be disclosed to research participants? Am
J Bioeth. 2013;13:3-8.
Ενας απο τους λογους που θελουν το ακαταδιωκτο οι Προφεσσορες.
Αντε και καλη ψυχη Μεταλλαγμενε το επομενο φθινοπωρο θα τα πουμε,εαν φθασεις ως εκει.
